Breaking News, Collaborations & Alliances

Domain Therapeutics & Chime Biologics Sign Manufacturing Service Agreement

Chime Biologics to ensure stable cell line development and DT-7012 candidate manufacturing to support clinical trials.

Author Image

By: Charlie Sternberg

Associate Editor

Domain Therapeutics, a clinical-stage global biopharmaceutical company developing drug candidates in immuno-oncology, and Chime Biologics, a Contract Development and Manufacturing Organization (CDMO), have signed a manufacturing service agreement for the production of Domain’s Treg depleting anti-CCR8 antibody candidate, DT-7012.   This phase of manufacturing aims to deliver an effective therapeutic for cancer patients worldwide.   Under the terms of the agreement, Chime Biologics will...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters